FDA Approves Gleevec to Prevent Recurrence of Rare Gastrointestinal Cancer

[News Reader]

The U.S. Food and Drug Administration today approved Gleevec (imatinib mesylate) for a new indication – keeping cancer from growing in patients following surgical removal of a gastrointestinal stromal tumor or GIST.

More... (http://www.fda.gov/bbs/topics/NEWS/2008/NEW01931.html)